Methods
DISEASE, SECONDARY, INFLUENZA
This secondary analysis of a randomized clinical trial was a prespecified analysis of the INVESTED trial, a pragmatic, randomized, double-blind, active comparator trial conducted at 157 participating centers in the US and Canada from September 2016 to July 2019. Follow-up was completed in July 2019. Patients with high-risk CV disease previously hospitalized for either MI in the past 12 months or HF in the past 24 months were randomized to high-dose or standard-dose influenza vaccine. The protocol and primary results have been previously published (